Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Payables (2016 - 2026)

Orthofix Medical has reported Payables over the past 17 years, most recently at $54.7 million for Q1 2026.

  • For the quarter ending Q1 2026, Payables rose 21.05% year-over-year to $54.7 million, compared with a TTM value of $54.7 million through Mar 2026, up 21.05%, and an annual FY2025 reading of $58.4 million, up 19.65% over the prior year.
  • Payables came in at $54.7 million for Q1 2026, down from $58.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $58.4 million in Q4 2025 to a low of $27.4 million in Q1 2022.
  • Median Payables over the past 5 years was $48.8 million (2024), compared with a mean of $46.0 million.
  • The sharpest move saw Payables soared 111.45% in 2023, then decreased 20.95% in 2025.
  • Over 5 years, Payables stood at $27.6 million in 2022, then soared by 111.45% to $58.4 million in 2023, then fell by 16.37% to $48.8 million in 2024, then rose by 19.65% to $58.4 million in 2025, then dropped by 6.35% to $54.7 million in 2026.
  • Per Business Quant, the three most recent readings for OFIX's Payables are $54.7 million (Q1 2026), $58.4 million (Q4 2025), and $50.5 million (Q3 2025).